NBY  Novabay Pharmaceuticals Inc.




Consumer Durables


Major Pharmaceuticals

Market Cap.


Vuru Grade


Current Price

+0.12 (+3.05%)

Company Metrics

  • P/E 0
  • P/S 6.13
  • P/B 27.9
  • EPS -3.87
  • Cash ROIC 921.20%
  • Cash Ratio 0.51
  • Dividend 0 / N/A %
  • Avg. Vol. 122,652.00
  • Shares 2.78M
  • Market Cap. 45.57M

Company Description

NovaBay Pharmaceuticals Inc., a clinical stage biotechnology company, engages in developing proprietary and patented topical Aganocide compounds for the treatment and prevention of various infections without causing bacterial resistance. Its Aganocide compounds are synthetic anti-infective product candidates with equivalent activity to the active antimicrobial molecules generated within white bloo... more

Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow


NovaBay Pharmaceuticals Inc.
MarketWatch - Jul 16, 2010
NovaBay Pharmaceuticals Inc. NYSE MKT: NBY. GO. Set Alerts · Find a Broker · Join TD Ameritrade · Market Index · Overview Profile News Charts Financials Historical Quotes Analyst Estimates Options SEC Filings Insiders.
News NovaBay Pharmaceuticals Inc.NBY
Wall Street Journal - Feb 11, 2011
News NovaBay Pharmaceuticals Inc.NBY. Significant News Only. 09/19/16; Press Release. NovaBay Pharmaceuticals' Auriclosene(R) Demonstrates Statistically Significant and Clinically Meaningful Results in Phase 2b Study for the Prevention of Urinary ...
Company Update (NYSE:NBY): NovaBay Pharmaceuticals, Inc.'s Auriclosene ...
Smarter Analyst - Sep 19, 2016
NovaBay Pharmaceuticals, Inc. (NYSEMKT:NBY) announces that data from a Phase 2b clinical study with Auriclosene Irrigating Solution (AIS) demonstrated statistically significant and clinically meaningful results in the prevention of urinary catheter ...
Novabay Pharma boosted by catheter blockage trial - Proactive Investors USA & Canada
Where Does NovaBay Pharmaceuticals, Inc. (NYSEMKT: NBY) Have Its Focus This Year?
Scibility Media - Aug 15, 2016
NovaBay Pharmaceuticals, Inc. (NYSEMKT: NBY) has set for itself many targets to hit before the end of 2016. But there is one that the management of the company has been talking about repeatedly: achieving positive cash flow.
NovaBay Pharmaceuticals' Neutrox ® Product Line Receives CE Mark and ISO ...
Business Wire (press release) - Sep 12, 2016
EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company focusing on commercializing prescription Avenova┬« lid and lash hygiene in the domestic eye care market, announces that its ...
NovaBay Pharmaceuticals (NYSE:NBY) product line receives CE mark & ISO ... - Benchmark Monitor
NovaBay Pharmaceuticals Reports 2016 Second Quarter Financial Results
Business Wire (press release) - Aug 11, 2016
BUSINESS WIRE)--NovaBay Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company focusing on commercializing its prescription Avenova lid and lash hygiene product for the domestic eye care market, reports financial results for the three ...
NovaBay Pharmaceuticals' (NBY) CEO Mark Sieczkarek on Q2 2016 Results ... - Seeking Alpha
NovaBay Pharmaceuticals Inc (AMEX:NBY) Stock Technicals Hit Strength
CML News - Aug 15, 2016
This is a technical analysis stock rating for NovaBay Pharmaceuticals Inc (AMEX:NBY) . The company has a four bull technical rating which indicates some strength.
NovaBay Pharmaceuticals, Inc. (NBY) Updated Broker Price Targets
The De Soto Edge - Sep 29, 2016
Market analysts have recently updated their ratings and price targets on shares of NovaBay Pharmaceuticals, Inc. (NBY).
NovaBay Pharma (NBY) Names Mark Sieczkarek as Permanent CEO
StreetInsider.com - Jun 13, 2016
NovaBay Pharmaceuticals, Inc. (NYSE: NBY) announces the appointment of Mark M. Sieczkarek as President and Chief Executive Officer, effectively immediately.
15 Stocks Moving In Monday's Pre-Market Session
Benzinga - Sep 19, 2016
Infoblox Inc (NYSE: BLOX) shares rose 15 percent to $26.25 in pre-market trading as the company announced its acquisition by Vista Equity Partners for $26.50 per share in cash.